Skip to main content
×
×
Home

Improving physical health monitoring in secondary care for patients on clozapine

  • Philipp J. Bolton (a1)
Abstract
Aims and method

To assess how well psychiatric teams follow up abnormal results from physical health monitoring of patients in a secondary care clozapine clinic compared with follow-up in a specialist secondary care physical health clinic, using an audit/re-audit method of comparison. Prevalence data for cardiovascular risk factors within the clinic population were also obtained.

Results

Substantial and statistically significant (P < 0.01) improvements in follow-up of abnormal results were made following the introduction of a specialist clinic compared with treatment as usual. Prevalence of all cardiovascular risk factors among the patients on clozapine was very high compared with the general population.

Clinical implications

Patients on clozapine have significant and multiple cardiovascular risk factors, which may be best managed within a specialist secondary care physical health clinic that can follow up abnormal results and coordinate care across primary and secondary care.

  • View HTML
    • Send article to Kindle

      To send this article to your Kindle, first ensure no-reply@cambridge.org is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about sending to your Kindle. Find out more about sending to your Kindle.

      Note you can select to send to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be sent to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

      Find out more about the Kindle Personal Document Service.

      Improving physical health monitoring in secondary care for patients on clozapine
      Available formats
      ×
      Send article to Dropbox

      To send this article to your Dropbox account, please select one or more formats and confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your <service> account. Find out more about sending content to Dropbox.

      Improving physical health monitoring in secondary care for patients on clozapine
      Available formats
      ×
      Send article to Google Drive

      To send this article to your Google Drive account, please select one or more formats and confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your <service> account. Find out more about sending content to Google Drive.

      Improving physical health monitoring in secondary care for patients on clozapine
      Available formats
      ×
Copyright
Corresponding author
Philippa J. Bolton (philippa.bolton@ntw.nhs.uk)
Footnotes
Hide All

Declaration of interest

None.

Footnotes
References
Hide All
1 Newman, SC, Bland, RC. Mortality in a cohort of patients with schizophrenia: a record linkage study. Can J Psychiatry 1991; 36: 239–45.
2 Nasrallah, HA, Meyer, JM, Goff, DC, McEvoy, JP, Davis, SM, Stroup, TS, et al. Low rates of treatment for hypertension, dyslipidemia and diabetes in schizophrenia: data from the CATIE schizophrenia trial sample at baseline. Schizophr Res 2006; 86: 1522.
3 National Institute for Health and Clinical Excellence. Guidelines for Schizophrenia (Clinical Guideline 82). NICE, 2006 (http://guidance.nice.org.uk/CG82/NiceGuidance/pdf/English).
4 Barnes, TRE, Paton, C, Cavanagh, MR, Hancock, E, Taylor, D. A UK audit of screening of metabolic side effects of antipsychotics in community patients. Schizophr Bull 2007; 33: 1397–403.
5 Fontaine, KR, Heo, M, Harrigan, EP, Shear, CL, Lakshminarayanan, M, Casey, DE, et al. Estimating the consequences of antipsychotic induced weight gain on health and mortality rates. Psychiatry Res 2001; 101: 277–88.
6 Taylor, D, Paton, C, Kerwin, R. The Maudsely 2005–2006 Prescribing Guidelines, 8th edn. Taylor & Francis, 2005.
7 Which atypical antipsychotic drug for schizophrenia? Drug Ther Bull 2004; 42: 5760.
8 National Institute for Health and Clinical Excellence. Hypertension: Management of Hypertension in Adults in Primary Care (Clinical Guideline 34). NICE, 2006 (http://www.nice.org.uk/nicemedia/pdf/CG034NICEguideline.pdf).
9 National Institute for Health and Clinical Excellence. Type 1 Diabetes: Diagnosis and Management of Type 1 Diabetes in Children, Young People and Adults (Clinical Guideline 15). NICE, 2004 (http://www.nice.org.uk/nicemedia/pdf/CG015NICEguideline.pdf).
10 Smellie, WSA. Testing pitfalls and summary of guidance in lipid management. BMJ 2006; 333: 83–6.
11 Smellie, WSA, Forth, J, Bareford, D. Best practice in primary care pathology: review 3. J Clin Pathol 2006; 59: 1116.
12 Smellie, WSA, Forth, J, Ryder, S, Galloway, MJ, Wood, AC, Watson, ID. Best practice in primary care pathology: review 5. J Clin Pathol 2006; 59: 1229–37.
13 Scanlan, M, Houltram, B. A Care Map for the Assessment and Management of Atypical Antipsychotic Side Effects. University College, Northampton, 2006.
14 Henderson, DC, Caligero, E, Gray, C. Clozapine, diabetes mellitus, weight gain, and lipid abnormalities: a five-year naturalistic study. Am J Psychiatry 2000; 157: 975–81.
15 Henderson, DC, Daley, TB, Kunkel, L, Rodrigues-Scott, M, Koul, P, Hayden, D. Clozapine and hypertension: a chart review of 82 patients. J Clin Psychiatry 2004; 65: 686–9.
16 Lamberti, JS, Costea, GO, Olson, D, Crilly, JF, Maharaj, K, Tu, X, et al. Diabetes mellitus among outpatients receiving clozapine: prevalence and clinical – demographic correlates. J Clin Psychiatry 2005; 66: 900906.
17 Lamberti, J, Olson, D, Crilly, J, Olivares, T, Williams, GC, Tu, X, et al. Prevalence of metabolic syndrome amongst patients receiving clozapine. Am J Psychiatry 2006; 163: 1273–6.
18 Ucok, A, Soygur, H, Atakli, C, Kuscu, K, Sartorius, N, Duman, ZC, et al. The impact of antistigma education on the attitudes of general practitioners regarding schizophrenia. Psychiatry Clin Neurosci 2006; 60: 439–43.
Recommend this journal

Email your librarian or administrator to recommend adding this journal to your organisation's collection.

BJPsych Bulletin
  • ISSN: 1758-3209
  • EISSN: 1758-3217
  • URL: /core/journals/bjpsych-bulletin
Please enter your name
Please enter a valid email address
Who would you like to send this to? *
×

Metrics

Full text views

Total number of HTML views: 0
Total number of PDF views: 15 *
Loading metrics...

Abstract views

Total abstract views: 182 *
Loading metrics...

* Views captured on Cambridge Core between 2nd January 2018 - 24th June 2018. This data will be updated every 24 hours.

Improving physical health monitoring in secondary care for patients on clozapine

  • Philipp J. Bolton (a1)
Submit a response

eLetters

No eLetters have been published for this article.

×

Reply to: Submit a response


Your details


Conflicting interests

Do you have any conflicting interests? *